NIFTY 50 22,231.80 -1.64%SENSEX 71,593.24 -1.44%NIFTY BANK 54,515.05 -0.98%INDIA VIX 15.28 +10.01%NIFTY 100 23,266.75 -1.82%NIFTY MIDCAP 50 16,530.90 -2.71%NIFTY SMALLCAP 100 19,050.10 -2.34%IT 27,736.60 -0.08%Automobiles 24,512.70 -2.49%Metals 11,870.05 -3.55%Energy 35,649.30 -2.82%Realty 796.60 -3.16%Pharma 25,823.25 -2.32%FMCG 43,898.05 -2.02%PSU banks 7,995.95 -1.15%
NIFTY 50 22,231.80 -1.64%SENSEX 71,593.24 -1.44%NIFTY BANK 54,515.05 -0.98%INDIA VIX 15.28 +10.01%NIFTY 100 23,266.75 -1.82%NIFTY MIDCAP 50 16,530.90 -2.71%NIFTY SMALLCAP 100 19,050.10 -2.34%IT 27,736.60 -0.08%Automobiles 24,512.70 -2.49%Metals 11,870.05 -3.55%Energy 35,649.30 -2.82%Realty 796.60 -3.16%Pharma 25,823.25 -2.32%FMCG 43,898.05 -2.02%PSU banks 7,995.95 -1.15%
Finomin
/
Sign in
HHomeSCScreenerMFMFsAUGoldNWNews
Home › Stocks › Gland Pharma Ltd
GP

Gland Pharma Ltd

GLAND · NSE Healthcare
₹3,079.10
-71.50 (-2.27%) today
Compare
OverviewSentimentTechnicalsFinancialsForecastsPeersHoldingsEventsNews
+104.80 (+3.52%)
7 Sep 268 Oct 26

Sentiment

Street mood
—
No analyst coverage is collected for this company.
BuyHoldSell
Retail pulse · — votes this week
——
Community sentiment is not collected on this site.

Key metrics

Market cap
₹47,225 Cr
P/E
33.4
ROE
12.8%
Dividend yield
0.73%
52-week high
₹2,975.00
52-week low
₹1,574.00

Technical indicators

Computed from 248 daily closes to 7 Oct 26. Every moving-average row is read against that day's close of 3,150.60.
Close is above its 10-, 20-, 30-, 50-, 100- and 200-day simple moving averages.
The MACD line (12, 26) is above its 9-period signal line.
RSI (14) is 67.79, above the 50 midpoint of its 0–100 range.
Of the 23 measures below that have a reference level, 23 are above it.
Moving averages
PeriodSMA (₹)Close isEMA (₹)Close is
10
2,945.25
above
2,969.63
above
20
2,937.79
above
2,936.33
above
30
2,922.96
above
2,902.09
above
50
2,841.38
above
2,817.02
above
100
2,588.78
above
2,604.96
above
200
2,167.40
above
2,285.22
above
Oscillators
IndicatorValueReference levelValue is
RSI (14)
67.79
50
above
Stochastic %K (14, 3, 3)
79.29
50
above
Stochastic %D (14, 3, 3)
60.96
50
above
MACD line (12, 26, 9)
44.63
Signal 36.10
above
CCI (20)
298.99
0
above
Awesome Oscillator (5, 34)
45.77
0
above
Momentum (10)
234.00
0
above
Williams %R (14)
-5.81
-50
above
Bull Power (13)
213.21
0
above
Bear Power (13)
61.21
0
above
Ultimate Oscillator (7, 14, 28)
60.71
50
above
Directional movement
ADX (14)
26.80
+DI (14)
33.85
-DI (14)
11.33
ADX measures how large the directional movement has been, not which way it went, so it has no reference level and takes no part in the count above.

A reference level is a property of the formula, not a threshold for action: it is the midpoint of the measure’s own range, or zero, or its own signal line, or the closing price. Saying a number sits above or below it is a statement about the number.

These are the standard published formulas — simple and exponential moving averages, RSI, the stochastic oscillator, MACD, CCI, ADX, the Awesome Oscillator, momentum, Williams %R, Elder-ray bull and bear power, and the Ultimate Oscillator — computed here from the daily closing prices of this share, the same series drawn in the chart above.

Every figure describes price behaviour that has already happened. None of it is a forecast, a target, a rating or a recommendation to deal in this security, and nothing on this page should be read as one. Educational and informational purposes only.

Financial trend ₹ thousand Cr

RevenueNet profit
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM

Peers

CompanyPrice (₹)P/EROE1Y return
A peer set is not published for this company.

Forecasts

Consensus of — analysts covering the stock
Price target · 12M
Low —Avg —High —
Average target implies — from the current price.
Analyst ratings
Buy—
Hold—
Sell—

Fair-value sandbox

FREE — usually behind a paywall
Tweak the assumptions; the target updates instantly. Your model, not our advice.
Revenue growth · next 5Y10% /yr
Operating margin15%
Exit P/E · year 533×
Discount rate
Implied fair value
₹2,908
-5.6% vs current ₹3,079.10
Your assumptions, your arithmetic — not a valuation or a recommendation.
Simple 5-year earnings model on FY26 EPS of ₹92.2. Assumptions are yours — not a recommendation.

Mutual funds invested

Top funds holding the stock, by share of market cap held
Fund · top 5Market-cap held
HDFC Flexi Cap Fund
GROWTH
0.1632%
ICICI Pru Bluechip Fund
GROWTH
0.1607%
SBI Equity Hybrid Fund
GROWTH
0.0748%
Nippon India Large Cap
GROWTH
0.0744%
UTI Nifty 50 Index Fund
GROWTH
0.0547%
Compare 3-month MF holding change on the screenerGo to screener ›

Health check ALL CHECKS FREE

Five checks across value, growth and risk
Return on equity
12.8%
›
Price to earnings
33.4
›
Dividend yield
0.73%
›

Shareholding pattern

Promoters51.77%
Foreign institutions8.74%
Domestic institutions30.44%
Public9.06%

Insider & bulk deals

Insider and bulk-deal filings are not collected on this site.
Deals above ₹10 Cr reported in the last 90 days.

In the news

About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Founded—
Headquarters—
IndustryPharmaceuticals